13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA209-274

    Acronym: 

    CA209-274

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Other
    Trial Type Treatment
    Phase Phase III Tumour Stream Urothelial carcinoma
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Other
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Urothelial carcinoma
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase III randomised, double-blind, multi-center study of adjuvant nivolumab vs. placebo in subjects with high risk invasive urothelial carcinoma

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Lyell McEwin Hospital Andy Phay andy.phay@sa.gov.au 08 8282 0833 Recruiting